Evidence map›Paper›PMID 27795306›Full record

ReviewClinical microbiology reviews2017

Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C.

Eleanor M Wilson, Elana S Rosenthal, Sarah Kattakuzhy, Lydia Tang, Shyam Kottilil

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical microbiology reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Eleanor M WilsonInstitute of Human Virology, University of Maryland School of Medicine, University of Maryland, Baltimore, Maryland, USA.
Elana S RosenthalCritical Care Medicine Department of the NIH Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Sarah KattakuzhyInstitute of Human Virology, University of Maryland School of Medicine, University of Maryland, Baltimore, Maryland, USA.
Lydia TangInstitute of Human Virology, University of Maryland School of Medicine, University of Maryland, Baltimore, Maryland, USA.
Shyam KottililInstitute of Human Virology, University of Maryland School of Medicine, University of Maryland, Baltimore, Maryland, USA skottilil@ihv.umaryland.edu.
National Institutes of Health Clinical Center · USUniversity of Maryland, Baltimore · US

Funding

Analysis of Stored Samples Collected Using Previously Expired ProtocolsZIACL009021 · CLC · CLINICAL CENTER · PI MASUR, HENRY · 2015 to 2024
$0k
6 · The paper itself

Abstract

Directly acting antiviral (DAA) combination therapies for chronic hepatitis C virus (HCV) infection are highly effective, but treatment decisions remain complex. Laboratory testing is important to evaluate a range of viral, host, and pharmacological factors when considering HCV treatment, and patients must be monitored during and after therapy for safety and to assess the viral response. In this review, we discuss the laboratory tests relevant for the treatment of HCV infection in the era of DAA therapy, grouped according to viral and host factors.

Indexed as

Antiviral AgentsClinical Decision-MakingDrug Resistance, ViralHepacivirusHepatitis C, ChronicHumansViral LoadAntiviral Agentsdirectly acting antiviral therapyhepatitis C virusviral resistance

Identifiers

PMID27795306
PMCPMC5217793
OpenAlexW2532293708

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.